A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Condition:   Asthma
Interventions:   Drug: Benralizumab;   Other: Placebo
Sponsor:   AstraZeneca
Not yet recruiting – verified August 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *